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Abstract
Background: Pirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal
models of lung, liver and renal fibrosis. These pathologies share many fibrogenic pathways with an abnormal
fibrous wound-healing process; consequently, tissue repair and tissue regeneration-regulating mechanisms are
altered.
Objective: To investigate the usefulness of PFD as an antifibrotic agent in clinical and experimental models of
fibrotic disease.
Conclusions: There is a growing understanding of the molecular effects of PFD on the wound healing
mechanism, leading to novel approaches for the management of fibrosis in lung, liver and renal tissues. Although
the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that
include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease.
Introduction
Pirfenidone (PFD) is a pyridine(5-methyl-1-phenyl-2-(1H)-
pyridone) with a simple chemical structure (Figure 1),
which was initially developed as an antihelminthic and
antipyretic agent [1]. PFD is very soluble in alcohol and
chloroform; in aqueous solutions, the maximum concen-
tration is 2%. The PFD molecule is able to move through
cell membranes without requiring a receptor. When admi-
nistered orally, PFD is easily absorbed in the gastrointest-
inal (GI) tract, reaching most tissues and crossing the
blood-brain barrier. After oral administration, PFD reaches
its maximum levels in blood after 1 to 2 hours and is
almost fully eliminated in urine after another 6 hours.
Regarding its safety, most studies have reported no signifi-
cant toxicity attributable to the drug at doses of around
2500 mg/day; minor side effects observed include nausea,
photosensitivity and GI issues.
Pharmacokinetics of PFD in human and
animal models
Studies on the pharmacokinetics and metabolism of PFD
conducted by Shi et al [2] evaluated the pharmacokinetics
of single and multiple oral doses of PFD in healthy adults
in a randomized, dose-escalating study. The drug was
rapidly absorbed (tmax = 0.33 to 1 hours) and cleared (t1/2
= 2 to 2.5 hours). Pharmacokinetic parameters after multi-
ple doses were similar to those after single doses, and con-
comitant intake of food reduced by 20% the rate and
extent of absorption, which are associated with better tol-
erability of PFD. No significant sex differences were noted
for the pharmacokinetic variables. Rubino et al [3]
reported decreased rate of PFD absorption in adults when
the drug was given with food. Analysis of adverse events
(AEs) revealed a correlation between PFD Cmax and the
risk of AEs associated with the GI system, suggesting that
food may reduce the risk of certain AEs associated with
PFD administration, which may improve tolerability. In
mice, Cho et al [4] observed that plasma PFD levels fell
rapidly, with a mean residence time of 6.3 min, which
agrees with the rapid disappearance of the drug. The
volume of distribution at steady state (Vdss) was 0.71 ml/g,
indicating that moderate extravascular distribution
occurred within 5 min, with the drug reaching the follow-
ing areas in descending order: kidney, liver, ventricle, lung,
spleen, pancreas, testes, GI system, brain, skeletal muscle,
adrenal glands and epididymal fat pad. Two metabolites
were identified, which seem to be produced from
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lowed by subsequent formation of the carboxylic acid.
Braim [5] observed mild and temporal effects during
PFD administration in horses, including tachycardia and
muscle fasciculations, effects that stopped when the
infusion ended. By the end of the 5 min infusion, PFD
and its two main metabolites, hydroxypirfenidone and
carboxypirfenidone, were detected, and mean peak
plasma concentration of PFD was 182.5 μmol/L. Forty
minutes after infusion, mean peak plasma concentra-
tions of hydroxypirfenidone and carboxypirfenidone
were 1.07 and 3.4 μmol/L respectively. No parent drug
or metabolites were detected at 24 hours.
In a sheep model, Bruss et al [6], observed that
plasma PFD disappeared in accordance with first order
kinetics with a clearance of 1.2 l/kg/h, a half-life of 24
min and distribution volume of 0.71 l/kg. After 48 h,
the largest quantities were found in lungs, liver and the
intestinal wall. In addition, the main metabolites were
found in plasma and urine (half-life of 44 min); addi-
tional metabolites found in urine were hydroxypirfeni-
done glucuronide and acetoxypirfenidone.
Approximately 80% of the tracer eventually appeared in
the urine, of which approximately 50% was in the form
of identifiable metabolites. Less than 1% of the dose
appeared in the urine in the form of the parent drug.
Quantitatively, most of the metabolites appeared in the
urine within 2 h. Thus, these pharmacokinetic results
support a tied regimen of PFD in patients with fibrotic
disease.
PFD has been tested in a variety of cellular and animal
models of inflammation and fibrosis, and has been
shown to hav eanti-inflammatory, antioxidative stress
and antiproliferative properties. PFD is known to regu-
late key fibrotic cytokines and growth factors. It inhibits
several inflammatory mediators, has an antioxidant
effect, and restores immune response balance. Beneficial
effects have been shown for PFD in the treatment of
fibrotic disease, including renal, liver and pulmonary
fibrosis and multiple sclerosis (MS), conditions that
share the pathology of abnormal deposition of collagen,
which is determinant of clinical outcome. In these fibro-
sis-related diseases, the amount of collagen deposited in
the tissue is controlled by the balance between synthesis
(regulated at the transcriptional and translational level)
and degradation of collagen in extracellular matrix
(ECM) by matrix metalloproteinases (MMPs), which are
regulated by tissue inhibitors of metalloproteinases
(TIMPs). In fibrosis, the positive balance to collagen
synthesis is influenced by production of transforming
growth factor TGFb and other growth factors, which
can be downregulated by PFD.
Currently, several clinical trials using PFD for various
diseases have been completed; these include studies on
pulmonary fibrosis associated with Hermansk-Pudlak
syndrome, focal segmental glomerulosclerosis, idiopathic
pulmonary fibrosis, hypertrophic cardiomyopathy, kid-
ney disease in patients with diabetes, neurofibromatosis
type 1, plexiform neurofibromas, and fibrosis caused by
radiation therapy for cancer. In addition, an open-label
study on the long-term safety of PFD in patients with
idiopathic pulmonary fibrosis has been devised, and
there are studies investigating use of PFD as a non-inva-
sive treatment for uterine leiomyomas, its influence on
heart function and exercise capacity in patients with
hypertrophic cardiomyopathy, its usefulness as a perme-
ability factor in focal segmental glomerulosclerosis [1],
and its benefits as a treatment for hypertrophic scars
caused by burns in pediatric patients (Armendariz-Bor-
unda et al., unpublished data).
Elucidation of fibrogenic mechanisms is fundamental
to identify novel potential therapies, and PFD may be a
Figure 1 Chemical characteristics of the pirfenidone molecule.
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if further studies are required. In this article, we
describe the therapeutic mechanisms of PFD underlying
its anti-inflammatory, antifibrotic and antioxidative
stress effects, and review the available in vitro and in
vivo models and the clinical trials in which PFD has
been used as therapy. We summarize the main molecu-
lar mechanisms that are triggered by PFD (Figure 2),
and conclude with an examination of fibrosis reduction
in the liver (most mechanisms show an equivalent part
for fibrosis in lung and renal tissues).
Three steps in the onset of fibrogenesis
Three important events must be considered to obtain an
integral understanding of fibrogenesis: oxidative stress,
inflammation and finally fibrosis. The initial biological
response to cellular damage includes inflammation and
oxidative stress responses. If the insult continues, the
anti-inflammatory mechanisms are not sufficient, and a
cumulative effect occurs, resulting in greater tissue
damage and eventually leading to fibrosis.
Oxidative stress is often associated with fibrogenesis
occurring in the liver, lung, arteries and nervous system,
because many fibrotic agents stimulate free radical reac-
tions, either directly or through inflammatory stimuli. It
is proposed that in fibrotic disorders, a weakened anti-
oxidant defense may define disease susceptibility. In sev-
eral models, antioxidant supplementation produced a
significant reduction in fibrotic progression, reducing
the extent of oxidative stress and/or lipid peroxidation
[7,8]. It has been reported that in the sequence of events
leading to fibrosis, oxidative stress and lipid peroxida-
tion precede, or are concomitant with, HSC activation
and collagen deposition [9] From experimental studies,
it was shown that NO production was able to prevent
both lipid peroxidation and collagen deposition [10,11].
Antioxidants such as silymarin [12,13] a-tocopherol
[14,15] silybin [16] and S-adenosylmethionine [17] also
produce beneficial effects in fibrotic disorders.
Free radicals appear to modulate the activity of phago-
cytes and ECM-producing cells. Lipid peroxidation and
certain lipid peroxidation products induce genetic over-
expression of fibrogenic cytokines, which promote con-
nective tissue deposition, and also induce increased
transcription of collagen genes, key molecules in the
altered mechanisms of fibrosis. Both events can be
downregulated, at least in experimental models, by use
of antioxidants [18].
For a better understanding of general antioxidant
mechanisms, specialized literature is available [19].
However, even when literature exists on the effects of
PFD in activation/repression of antioxidant genes, our
knowledge of many processes is incomplete [20,21].
Fibrosis may result from sustained inflammatory pro-
cesses. Tumor necrosis factor (TNF)-a is a vital compo-
nent of the inflammatory process, and its aberrant
Figure 2 Molecular mechanisms of pirfenidone in the reduction in fibrosis. Green indicates the mechanisms promoted by pirfenidone; red
indicates the mechanisms that are inhibited by this drug.
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tory states. The anti-inflammatory role of PFD has been
exhaustively examined in several models of inflamma-
tion. Administration of PFD significantly reduced
secreted levels of bioactive and cell-associated TNF-a
after stimulation with lipopolysaccharide [22].
Finally, persistent injury results in a chronic wound
healing response that eventually leads to fibrosis. This
fibrotic response shares common features in multiple
organs that can be affected by these disorders. Experi-
mental evidence has indicated PFD as a collagen and
TGF-b production blocker, and as an activator of
MMPs, thus modulating the fibrogenic pathway [23].
Organs in which PFD has been tested as an
antifibrotic drug
Lung
A number of studies have been designed to assess the
molecular mechanism and the clinical efficacy and safety
of PFD when administered to treat lung diseases, includ-
ing interstitial pulmonary fibrosis, the experimental
bleomycin (BL) model of lung fibrosis, and several mod-
els of acute lung injury. This group of disorders is char-
acterized by scarring of deep lung tissue, leading to
shortness of breath and loss of functional alveoli, thus
limiting oxygen exchange. Etiologies include inhalation
of inorganic and organic dusts, gases, fumes and vapors,
use of medications, exposure to radiation, and develop-
ment of disorders such as hypersensitivity pneumonitis,
coal worker’s pneumoconiosis, silicosis and byssinosis
(occurs after exposure to cotton dust), among others.
In vitro models of lung fibrosis and PFD
Recently, it has been proposed that lung fibrosis is
caused in part by chronic oxidative stress and inflamma-
tion. Increased production of reactive oxygen species
(ROS), which leads to lipid peroxidation, oxidation of
DNA and proteins, and activation of pro-inflammatory
factors, has been observed in several in vitro lung mod-
els; PFD has been shown to diminish these pathological
states. For example, PFD suppressed Hermansky-Pudlak
syndrome (HPS)-1, alveolar macrophage cytokine and
chemokine secretion in vitro in a dose-dependent man-
ner [24] PFD was found to inhibit the responder fre-
quency of T-cell rearrangement (TCR)-stimulated CD4
cell total proliferation in vitro and in vivo,a n dt h ep r o -
liferation index of both CD4 and CD8 was reduced.
Additionally, PFD inhibited TCR-induced production of
multiple pro-inflammatory cytokines and chemokines.
Interestingly, there was no change in TGF-b production
by purified T cells, and PFD had no effect on the sup-
pressive properties of naturally occurring regulatory T
cells [25] In addition, the antifibrotic effect of PFD may
be mediated through inhibition of heat shock protein
47, a collagen-specific molecular chaperone, with a
resultant reduction in collagen synthesis in lung fibrosis
[26].
PFD in animal models of lung fibrosis damage
Since the first studies on PFD in lung fibrosis, several
recent experimental and clinical trials have provided evi-
dence of its role in decreasing fibrogenesis in the lung.
Interstitial pulmonary fibrosis is the result of a wide
variety of injuries to the lung, and involves inflamma-
tion, increase in cytokine levels, infiltration of immune
cells and increase in ECM production in response to
proliferating lung fibroblasts [27,28], leading to collagen
deposition in the lung interstitium. BL-induced lung
damage in rodents resembles this disease [29,30], and is
triggered by intratracheal instillation of BL (usually at a
dose of 5 to 7.5 U/kg/5 ml) in rodents, producing histo-
logical lesions and biochemical changes. Some of the
studies with PFD that use this model to assess antifibro-
t i ce f f e c t sa r el i s t e db e l o w ;i na l lc a s e s ,t h ed o s eo fP F D
was 5% of the weight of the diet fed to the animals
throughout the study. The results agreed with those for
PFD in other models such as cyclophosphamide-induced
fibrosis [31].
Iyer et al. [30] demonstrated that PFD retards the pro-
gression of an ongoing fibrotic process, and produces a
maximum reduction in collagen content of 40% at day
21, through suppression of lung inflammation. In addi-
tion, there are decreases in lung lipid peroxidation (a
marker of inflammation index), prolyl hydroxylase (PH)
activity (an enzyme responsible for post-translational
modification of collagen), hydroxyproline content, and
pro-collagen I and III mRNA accumulation. However,
PFD failed to shown any direct inhibitory effect on PH
activity in vitro, suggesting that it must be acting at the
transcriptional level. As a continuation of this work, Iyer
et al. [32] measured expression of the TGF-b gene in
the lungs after PFD treatment. They observed suppres-
sion in the influx of inflammatory cells and macro-
phages at day 7 post-instillation, and levels of TGF-b
mRNA significantly reduced by 33% at 7, 14 and 21
days, as revealed by nuclear run-off studies; TGF-b pro-
tein was also suppressed at 14 and 21 days. This effect
on TGF-b transcription was also seen in an amiodarone
model of lung fibrosis [33].
Furthermore, it was demonstrated that PFD treatment
inhibited synthesis of both platelet-derived growth factor
(PDGF)-A and -B isoforms by lung macrophages [34],
reduced inflammation and suppressed the BL-induced
increase in the levels of proteins and TGF-b,a n d
reduced the influx of neutrophils, macrophages and
lymphocytes in bronchoalveolar lavage (BAL) fluid at
early time points [35]. Using two doses of PFD (30 and
100 mg/kg) three times daily, PFD modulated various
pulmonary cytokines at the protein level, and the mini-
mum effective dose was found to be 30 mg/kg three
Macías-Barragán et al. Fibrogenesis & Tissue Repair 2010, 3:16
http://www.fibrogenesis.com/content/3/1/16
Page 4 of 11times daily. In the lung, PFD also decreased inflam-
matory edema, and reduced levels of hydroxyproline,
interleukin (IL)-1b, IL-6, IL-12, p40, monocyte chemoat-
tractant protein and interferon (IFN)-g [36] It also
reduced the elevation of lung basic fibroblast growth
factor, lung stroma cell derived factor-1a,a n dI L - 1 8
[36,32] By a different mechanism, induction of arginase,
a vital enzyme for collagen synthesis that metabolizes L-
arginine to urea and L-ornithine, is altered by PFD
treatment, and consequently, levels of collagen contents
were reduced in rat lung orthotopic transplants [37].
PFD has also been shown to have a potent anti-TNF-a
activity, promoting protection against acute allograft
injury [38] and acute lung injury [39] in mice. Addition-
ally, the mechanism of the protective effect of PFD
involves a decrease in oxygen radicals in experimental
models of acute respiratory distress syndrome [40].
In antigen-induced allergic models, sensitized mice or
guinea pigs developed a prominent pulmonary inflam-
mation 24 h after antigen challenge, reflected by a sig-
nificant increase in the number of recoverable total cells
and eosinophils in BAL samples. In both species, pre-
treatment with PFD (10 and 30 mg/kg) resulted in a
dose-dependent inhibition of antigen-induced pulmon-
ary inflammation, which was reflected by a significant
decrease in eosinophils and total cells in BAL samples
with the 30 mg/kg dose. In a non-allergic model of pul-
monary inflammation, rats challenged with intratracheal
LPS had a significant increase in neutrophils and total
cells in BAL samples, along with significant increases in
TNF-a and IL-6. Pre-treatment with PFD (3 and 30 mg/
kg) showed a dose-dependent inhibition of the LPS-
induced pulmonary inflammation, reflected by a signifi-
cant decrease in the number of total and neutrophilic
cells in BAL samples at both doses. Thus, PFD can inhi-
bit allergic and non-allergic inflammatory cell recruit-
ment, and its pulmonary anti-inflammatory activity is
independent of TNF-a inhibition [41].
Clinical trials using PFD for lung disease
Idiopathic pulmonary fibrosis (also known as crypto-
genic fibrosing alveolitis) is the most common form of
interstitial lung disease, and is characterized by chronic
progressive pulmonary parenchymal fibrosis. It is a
progressive clinical syndrome with unknown etiology;
the outcome is invariably fatal as no effective therapy
exists.
PFD has been evaluated for its tolerability and useful-
ness in patients with advanced idiopathic pulmonary
fibrosis and other lung diseases. Most reported a few
nonsignificant adverse effects (AEs), and found that the
drug is generally well tolerated. Raghu et al. [42] investi-
gated PFD as oral therapy in consecutive patients with
IPF in an open-label study. In this study, 54 patients
(mean age 62 years) were monitored for mortality,
change in lung function and AEs. The survival rates at 1
and 2 years were 78% and 63%, respectively. Patients
whose lung function had deteriorated before enrollment
appeared to stabilize after beginning treatment.
In a double-blind, randomized, placebo-controlled trial
(RPCT), the effects of PFD were measured by the
change in the lowest oxygen saturation by pulse oxime-
try (SpO2) during a 6-minute exercise test. The primary
endpoint from baseline to 6 months was not signifi-
cantly different, but in a subset of patients who main-
tained a SpO2 o f>8 0 %d u r i n gt h e6 - m i n u t ee x e r c i s e
test at baseline, there was a significant difference in
SpO2 i nt h eP F Dg r o u pa t6a n d9m o n t h s .P F Da l s o
enhanced percentage vital capacity, and episodes of
acute exacerbation of IPF occurred exclusively in the
placebo group [43].
T h ed i s e a s eH P Sp r o g r e s s i v ely evolves to fatal pul-
monary fibrosis. Treatment with PFD (800 mg three
times daily) for up to 44 months in an RPCT changed
pulmonary function values. Reduction in predicted
forced vital capacity (FVC) each year was 5% slower in
11 PFD-treated patients than in 10 placebo-treated
patients. Using data restricted to patients with an initial
FVC of > 50% of predicted values, patients in the PFD
group lost pulmonary function (FVC, forced expiration
volume in 1 second, total lung capacity, and diffusing
capacity for carbon monoxide) at a slower rate (> 8%/
year) than the placebo group. PFD appears to slow the
progression of pulmonary fibrosis in patients with HPS
who have significant residual lung function [44].
Given the lack of effectiveness of current therapy in
treating patients with IPF, these different points of evi-
dence suggest that PFD might be a useful treatment for
this deadly disease.
Liver
Liver fibrosis occurs as a consequence of ECM accumula-
tion, mainly of collagen types I and III, in response to
liver injury. This is triggered by the activation of hepatic
stellate cells (HSC), which change to a myofibroblast-like
phenotype, with a consequent increase in their synthesis
of matrix proteins that characterize fibrosis, such as
interstitial collagens [45]. In addition, there is increasing
evidence that liver fibrosis is a dynamic pathologic pro-
cess in which altered matrix degradation may also play a
major role. Extracellular degradation of matrix proteins is
regulated by MMPs produced by HSC, which in turn are
regulated by several mechanisms, including gene regula-
tion (transcription and proenzyme synthesis), cleavage of
the proenzyme to an active form, and specific inhibition
of activated forms by TIMPs [46].
In vitro models of liver fibrosis and PFD
In rat HSC, PFD at 1000 μM inhibited PDGF-induced
HSC proliferation, without any toxic effects. It also did
Macías-Barragán et al. Fibrogenesis & Tissue Repair 2010, 3:16
http://www.fibrogenesis.com/content/3/1/16
Page 5 of 11not affect HSC viability and did not induce apoptosis.
The inhibition in cell proliferation was not associated
either with variations in PDGF receptor autophosphory-
lation, or with activation of extracellular signal-related
kinase (ERK)1/2 or of the 70 kDa ribosomal S6 kinase
(pp70S6K), but PFD was able to inhibit PDGF-induced
activation of the Na
+H
+ exchanger involved in PDGF-
induced HSC proliferation. PFD also inhibited PDGF-
induced protein kinase C activation, type I collagen
accumulation and procollagen mRNA expression [47].
In sheep liver microsomes, PFD was found to be inef-
fective as a superoxide radical scavenger and in decom-
posing H2O2 and chelating iron; however, in a
deoxyribose degradation assay; PFD was a potent sca-
venger of hydroxyl radicals, which could be related to
its beneficial effects [20].
PFD in animal models of liver damage
PFD provides a unequivocal protective anti-inflamma-
tory effect against acute hepatic injury caused by D-
galactosamine/LPS in rats by inhibiting elevated TNF
levels and IFN-g, and reducing the induction of induci-
ble nitric oxide synthase (iNOS)/nitric oxide (NO) [48],
partly through the inhibition of nuclear factor B activa-
tion [49]. PFD also inhibits production of cytokine-
induced neutrophil chemoattractant and macrophage
inflammatory protein-2, (induced by IL-1b at posttran-
scriptional steps in hepatocytes) in the process of neu-
trophil recruitment and activation [50]. Previous data
from our group [51] showed that PFD is an effective
antifibrotic drug in two different experimental models of
fibrosis (basal laminar deposits (BLD) and chronic intox-
ication by carbon tetrachloride (CCl4)), significantly
decreasing levels of alanine aminotransferase (ALT),
aspartate aminotransferase and alkaline phosphatase
compared with saline-treated animals. Fibrotic areas
reduced by 50% in 4-week BDL rats, and by 70% in a
CCl4 model, along with hydroxyproline levels. The num-
ber of activated HSC decreased, and there was a reduc-
tion in gene expression of collagens I, III and IV, TGF-
b1, Smad-7, TIMP-1 and plasminogen activator inhibi-
tor (PAI)-1.
It has been shown that PFD maintains its antifibrotic
properties when administered after hepatic damage has
already occurred. Rats treated with dimethylnitrosamine
10 mg/kg for 5 weeks received a liquid diet containing
0.5% PFD starting from the third week. The PFD treat-
ment reduced the degree of liver injury, as determined
by ALT values and necroinflammatory score, which was
associated with reduced HSC proliferation and collagen
deposition. Treatment with dimethylnitrosamine pro-
duced a fold increase in transcript levels of TGF-b1,
TIMP-1 and MMP-2 of seven, seven, four and 15,
respectively. PFD downregulated the elevated levels of
these transcripts by 50 to 60%, which was associated
with a 70% reduction in collagen deposition and down-
regulation of TGF-b1a n do fM M P - 2m R N A ,t h et w o
substances mainly implicated in the degradation of nor-
mal ECM [52].
In bile duct ligation and CCl4 models of liver cirrhosis,
PFD treatment caused a reduction in inflammation and
in hepatic enzymes and bilirubin concentrations. It also
downregulated TGF-b1 and collagen I-a(COL1A1)
genes [21]. In addition, in this paper, our group demon-
strated the potent role of PFD as an antioxidant in vivo
compared with a well-known broad-spectrum antioxi-
dant such as diphenyleneiodonium. The antioxidant
capacity of PFD produced a 28% and 30% reduction,
respectively, in nitrite and malonyldealdehide concentra-
tions in the bile duct ligation model, and 52% and 38%
in the CCl4 model. Furthermore, PFD downregulated
gene expression of superoxide dismutase (SOD), catalase
(CAT) and iNOS. The functional activity of SOD and
CAT also decreased after PFD administration, raising
the possibility of using PFD for diseases accompanied by
oxidative stress.
Clinical trials using PFD for liver diseases
Owing to the wide range of etiologies that lead to fibro-
genesis in the liver, specific and effective therapies for
each kind of fibrosis remain elusive [53]. Furthermore,
the effectiveness of PFD in many cases depends on
inherited genetic polymorphisms that increase the risk
of developing advanced fibrosis in patients with estab-
lished liver fibrosis [54]. Despite this, in a pilot clinical
trial evaluating the safety and efficacy of PFD, 15
patients with established advanced liver disease caused
by chronic hepatitis C virus infection had improvements
in liver histology (necrosis, inflammation, steatosis,
fibrosis and cell regeneration) 12 months after oral PFD
therapy (1200 mg/daily). Liver cell regeneration was
detected in 70% of patients with differing degrees of
anti-proliferating cell nuclear antigen as measured by
immunostaining. Fibrosis was reduced in 30% of
patients by the end of the 12-month treatment, and
mRNAs coding for profibrogenic molecules such as
COL1A1, TGF-b1 and TIMP-1 were markedly downre-
gulated by the end of treatment. Quality of life, as mea-
sured by the Short Form (SF)-36 questionnaire imseen
markedly in all patients [55].
Kidney
PFD and in vitro models of renal fibrosis
Fibroblasts are activated in tubulointerstitial injury and
their presence is a marker of disease progression. A
well-characterized model of experimental renal disease
is the unilateral ureteral obstruction (UUO) which cul-
minates in tubulointerstitial fibrosis.
Cortical fibroblasts isolated from kidneys 3 days after
UUO were exposed to increasing PFD concentrations,
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a-smooth muscle actin and connective tissue growth
factor protein expression, although synthesis of collagen
was unaffected by PFD [56].
PFD in animal models of renal fibrotic damage
Using five-sixths nephrectomy rat model, the effect of
PFD on the progression of chronic renal failure was
examined. PFD-treated rats had inhibition of TGF-b1,
type IV and I mRNA collagen expression [57].
With the UUO model, rats had upregulation of
mRNA for collagen types I and IV, MMP-2 and TGF-
b1. In addition, a progressive increase in hydroxyproline
content was observed in the post-obstructed kidney
despite the release of obstruction, but these increases
were suppressed by PFD. Thus PFD can attenuate both
renal fibrosis and renal damage in this model, and
therefore could be clinically useful for preventing pro-
gressive, irreversible renal failure [58].
One more animal model in which the antifibrotic
properties of PFD were observed was the model of
chronic nephrotoxicity induced by ciclosporin (CsA),
which is characterized by tubulointerstitial fibrosis.
Treatment with PFD ameliorated CsA-induced fibrosis
by about 50%. PFD was associated with a decrease in
TGF-b1 expression, which in turn was associated with a
decrease in matrix deposition [59].
Additional proof of reduction in ECM by PFD was
observed in mouse mesangial cells, in which PFD
decreased TGF-b promoter activity, reduced TGF-b pro-
tein secretion, and inhibited TGF-b-induced Smad2-
phosphorylation, 3TP-lux promoter activity and genera-
tion of ROS. In addition, PFD treatment significantly
reduced mesangial matrix expansion and expression of
renal matrix genes. Thus, the renoprotective and antifi-
brotic PFD effects could be related, at least in part, to
its inhibition of RNA processing [60].
Streptozotocin (STZ)-induced diabetic rats treated
with PFD and spironolactone showed both reversal in
deposition of major ECM proteins, collagen and fibro-
nectin, and a number of functional changes. Fibrosis
leads to chronic impairment of cardiac and renal func-
tion, thus reversal of existing fibrosis may improve func-
tion and survival. Short-term treatment with PFD and
spironolactone reversed cardiac and renal fibrosis and
attenuated the increased diastolic stiffness, but without
normalizing cardiac contractility or renal function in
STZ-induced diabetic rats [61].
The ability of PFD to reverse markers of renal dys-
function in rats was also tested. Tacrolimus-induced
nephrotoxicity is thought to contribute to renal allograft
dysfunction and subsequent failure, a process that is
underpinned by alterations in mRNA expression of
genes involved in matrix metabolism. PFD caused a
decrease in collagen III and TIMP-1 mRNA expression,
suggesting that it could attenuate the limited fibrotic
potential of tacrolimus [62].
PFD and the angiotensin II type I receptor antagonist
candesartan cilexetil, given alone or in combination,
were tested in rats with chronic antiglomerular base-
ment membrane glomerulonephritis (anti-GBM GN).
The combination of both agents produced an improve-
ment in adsorption droplets and proteinuria in the glo-
meruli, and cortical collagen I mRNA expression was
also significantly decreased. Rats treated with PFD had
blood pressure values similar to control rats. Thus, the
beneficial effects of PFD on morphological changes in
anti-GBM GN were comparable with those of candesar-
tan, and these results suggest an additive effect of com-
bination treatment [63].
In a model of spontaneous progressive glomerulo-
sclerosis using FGS/Kist mice, PFD was evaluated for
the prevention of renal fibrosis; proteinuria levels were
lower in the PFD group compared with the control diet
group The sclerosis scores of the PFD groups at 3
months were also reduced. There was no significant dif-
ference between the PFD and control diet groups after
treatment for 1 or 2 months, but there was a significant
difference after treatment for 3 months, suggesting that
long-term administration of PFD is required to suppress
the progression of glomerulosclerosis and improve renal
function in the FGS/Kist mice [64].
In a vanadate-induced kidney fibrosis model in rats,
the antifibrotic effects of PFD were also seen. Treatment
with PFD reduced vanadate-induced increases in kidney
weight, RNA content and hydroxyproline levels. Histolo-
gical evaluation revealed that the severity of the lesions
in the vanadate-treated group was ‘moderate to severe’
before treatment with PFD; after treatment with PFD
for 41 days, the severity decreased to ‘mild’.T h ec o l -
lagen content of the kidney was also reduced after PFD
treatment [65].
Finally, PFD produced a modulation of apoptosis med-
iators in a chronic CsA-induced nephrotoxicity animal
model. PFD reduced the number of apoptosis-positive
cells induced by CsA. In addition, PFD downregulated
mRNA expression of CsA-induced p53 and Fas-ligand
and increased that of Bcl-xL, which had previously been
reduced by CsA. PFD significantly downregulated cas-
pase 3 expression, mostly on renal tubular epithelial
cells. Because apoptosis could partly explain the loss of
cells associated with fibrosis, the influence of PFD on
apoptosis-regulatory genes to cause a reduction in apop-
tosis may explain some of its antifibrotic properties [66].
Clinical trials using PFD for renal diseases
PFD was tested in patients with focal segmental glomer-
ulosclerosis. The monthly change in estimated glomeru-
lar filtration rate (GFR) was compared between baseline
and after treatment. Patients received angiotensin
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Page 7 of 11antagonist therapy if tolerated. In total, 18 patients com-
pleted a median of 13 months of PFD treatment; the
m o n t h l yc h a n g ei nG F Ri m p r o v e df r o mam e d i a no f
-0.61 ml/min per 1.73 m
2 at baseline to -0.45 ml/min
per 1.73 m
2., a median improvement in the rate of
decline of 25%. It was concluded that PFD slows renal
function decline in patients with focal segmental glo-
merulosclerosis [67].
Details of the clinical trials that used pirfenidone for
various fibrotic diseases are listed in Table 1.
Fibrogenesis in other tissues and organs
It was also observed that PFD reduces AEs such as cap-
sule contracture in mammary implants in an animal
model, Gancedo et al. [68] observed a reduction in cap-
sule thickness around submmamary tissue, along with a
decrease in fibroblast-like cell proliferation, and recruit-
ment and infiltration of inflammatory cells.
It has been shown that PFD reduces keloid formation
in an animal model. A keloid is a type of scar with
mainly type I and some type III collagen, which results
in an overgrowth of tissue at the site of a healed skin
injury. Keloids should not be confused with hyper-
trophic scars, which are raised scars that do not grow
beyond the boundaries of the original wound. In athy-
m i cn u d em i c e( n u - n u ) ,P F Ds i g n i f i c a n t l yr e d u c e dt h e
weight of keloid implants weight compared with control
implants at 60 and 90 days after implantation. PFD may
cause increased degradation and absorption of keloid
tissue [69].
Our own clinical data has demonstrated that a scar
reduction gel (Kitoscell™; Cell Therapy and Technol-
ogy, Mexico City, Mexico) with 8% PFD topically
administered during a 6-month period led to resolu-
tion of hypertrophic scars acquired after burns in
pediatric patients. There was a significant improvement
after treatment in all patients: 27.27% had a decrease
of 55%; 66.66% a decrease of 30 to 45%, and the
remainder a decrease of ≤ 30%, according to the Van-
couver scar scale [70].
Pesce E [71] compared the antirheumatic effect of
PFD with a positive control drug, oxyphenbutazone,
which is used in patients with rheumatoid arthritis (RA),
in a double-blind clinical trial in humans. It was found
that PFD was more effective than oxyphenbutazone in
providing relief from arthritic pain. In addition, a greater
number of patients reported a favorable response to oral
P F Dt h a nt oo r a lo x y p h e n b u t a z o n e .T h e r ew e r en os i g -
nificant differences between the PFD and oxyphenbuta-
zone groups in the number of patients who dropped out
from the trial or who tolerated the drugs for the 21 days
of the trial, indicating that PFD is a potential new ther-
apy for the management of RA, with few or no AEs,
unlike the steroidal and non-steroidal anti-inflammatory
drugs that are frequently used for this chronic debilitat-
ing disease.
Currently, there are no approved treatments for sec-
ondary progressive MS that stabilize or reverse the neu-
rological disabilities associated with this disease. Oral
PFD was found to stabilize and overcome the symptoms
of secondary progressive MS in a phase II double-blind
RPCT in patients who had advanced secondary progres-
sive MS that had been present for at least 12 months.
After 1 month of treatment with PFD, patients had
improvement in their Scripps Neurological Rating Scale
(SNRS) scores, and scores remained significantly
Table 1 Summary of the clinical trials that used pirfenidone for fibrosis-related diseases
Disease Dose and time Type of study Number
of
patient
Effects Reference
Interstitial
pulmonary
fibrosis
3600 mg/daily for
2 years
Open-label study 54 Increase in 1 and 2 year survival. Stabilized lung function. [42]
Interstitial
pulmonary
fibrosis
600 mg three times
daily for 12 months
Double-blind,
randomized, placebo-
controlled trial
107 Improvement in SpO2 during a 6-minute exercise test. No
episodes of acute exacerbation of IPF in PFD group.
[43]
Hermansky-Pudlak
syndrome
800 mg three times
daily for 44 months
Randomized, placebo-
controlled trial
11 Loss of pulmonary functions occurred at a slower rate. [44]
HCV related liver
disease
1200 mg/daily for
12 months
Open-label pilot study 15 30% of patients had less fibrosis after treatment.
Downregulation of Col I, TGFb and TIMP-1. Improvement
in quality of life (SF-36 test).
[55]
Focal segmental
glomerulosclerosis
800 mg three times
daily for 5 to 37
months
Open-label pilot study 18 Slowed renal function decline; improvement of 25% [67]
Hypertropic scars PFD 8% gel for 6
months
Open-label pilot study 33 Improvement in the Vancouver scar score in 66.6% of
patients.
[70]
HCV = hepatitis C virus; PFD = pirfenidone; SF = Short Form; SpO2 = lowest oxygen saturation by pulse oximetry; TGF = transforming growth factor;
TIMP = tissue inhibitor of metalloproteinase.
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Page 8 of 11improved for 3, 6 and 12 months compared with base-
line SNRS scores. By contrast, the SNRS scores of
patients on oral placebo were not significantly improved
compared with baseline scores [72].
Conclusions
The advantages of PFD clearly exceed any possible AE
ascribable to this drug. It obviously had powerful antifi-
brotic properties, as it can reduce oxidative, inflamma-
tory and pro-fibrogenic markers. As many therapeutic
agents target only one of these types of markers, but
still produce a reduction in, PFD seems to be a particu-
l a r l yv a l u a b l ed r u g .T h u s ,t h i sa g e n tc o u l db ea sap r o -
mising drug not just in animal models, but also in
clinical studies of fibrotic diseases, and eventually as a
therapy for such diseases.
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